Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

NCT05718323 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

44

Enrollment

NETWORK

Sponsor class

Conditions

SCLC,Extensive Stage
SLFN11-positive

Interventions

DRUG: Niraparib

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

[object Object]
[object Object]